This is the sixth corona vaccine approved by the European Medicines Agency.
European The Finnish Medicines Agency (EMA) recommends a marketing authorization for the use of the French-Austrian Valeva coronary vaccine in people aged 18 to 50 years.
The EMA assessment found that the vaccine met the EU criteria for effectiveness, safety and quality. This is the sixth Ema-approved coronary vaccine.
The vaccine was tested in a study involving around 3,000 people over the age of 30. The vaccine produced more antibodies in the study than the comparator vaccine Astra Zeneca Vaxzevria. For the time being, the mother limited the marketing authorization to those under 50 years of age, as it was not possible to conclude from the research sample how well the vaccine produces resistance in the elderly.
The side effects experienced by the study participants were mild and similar to those seen with other coronary vaccines: injection site tenderness, fatigue, headache, muscle pain, and nausea. The benefits of the vaccine outweigh the risks.
Vaccine is based on more traditional vaccine technology and contains inactivated or killed whole pathogens. Because the vaccine does not contain live pathogens, it cannot cause the disease itself. In addition, Valneva vaccine contains adjuvants.
Valneva does not need to be stored in the refrigerator, unlike some coronary vaccines. Easy storage allows, among other things, the transport of vaccines to developing countries.
Britain has approved the use of the Valvena vaccine in April, according to the news agency AFP.
The vaccine is given in two doses over 28 days.
#Coronavirus #European #Medicines #Agency #recommended #Valneva #marketing #authorization
